Show simple item record

dc.contributor.editorLópez-Fernández, Luis A.
dc.date.accessioned2022-03-21T16:29:33Z
dc.date.available2022-03-21T16:29:33Z
dc.date.issued2022
dc.identifierONIX_20220321_9783036533445_90
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/79654
dc.description.abstractAdverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.other5-fluorouracil
dc.subject.othercapecitabine
dc.subject.otherfluoropyrimidine
dc.subject.otherthymidylate synthase
dc.subject.otherthymidylate synthase enhancer region
dc.subject.otherupstream stimulatory factor 1
dc.subject.otheradverse drug reactions
dc.subject.otherpharmacogenomics
dc.subject.otherepistasis
dc.subject.otherrandom forest
dc.subject.otherstatin
dc.subject.othercardiovascular disease
dc.subject.othercolorectal cancer
dc.subject.otherpersonalised medicine
dc.subject.othertoxicity
dc.subject.other(es)citalopram
dc.subject.otherdrug-gene-interaction
dc.subject.otherdrug-drug-interaction
dc.subject.otherdrug-drug-gene-interaction
dc.subject.otherthe PharmLines initiative
dc.subject.otherantipsychotic agents
dc.subject.otherpharmacogenetics
dc.subject.othercytochrome P-450 enzyme system
dc.subject.otherpsychotic disorders
dc.subject.otherprecision medicine
dc.subject.otherdirect oral anticoagulants
dc.subject.otherclinical implementation
dc.subject.otheratorvastatin
dc.subject.otherSLCO1B1
dc.subject.otherHLA
dc.subject.othercutaneous adverse drug reaction
dc.subject.otherSCAR
dc.subject.othergenetic polymorphism
dc.subject.otherantiepileptics
dc.subject.otherCYP450 enzymes
dc.subject.otherplatelet reactivity
dc.subject.othersingle-nucleotide variants
dc.subject.otheracute coronary syndrome
dc.subject.otherclopidogrel
dc.subject.othergenotype
dc.subject.otherallele
dc.subject.otherpolymorphism
dc.subject.otherHLA B
dc.subject.otherCYP2C9*3
dc.subject.othercutaneous adverse drug reactions (CADRs)
dc.subject.otheranti-epileptic drugs (AEDS)
dc.subject.otherphenytoin (PHT)
dc.subject.othergenetic risk factors
dc.subject.otherSouth India
dc.subject.otherIndia
dc.subject.othercardiology
dc.subject.otheradverse events
dc.subject.otherguidelines
dc.subject.othern/a
dc.titlePharmacogenetics to Avoid Adverse Drug Reactions
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-3343-8
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036533445
oapen.relation.isbn9783036533438
oapen.pages220
oapen.place.publicationBasel


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/